Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708–20.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;18(3):684–92.

Article  CAS  PubMed  Google Scholar 

Optimizing Dosing in Oncology Drug Development. Friends of cancer research 2021. p. https://friendsofcancerresearch.org/sites/default/files/2021-11/Optimizing_Dosing_in_Oncology_Drug_Development.pdf.

Administration FaD. Project optimus: reforming the dose optimization and dose selection paradigm in oncology. 2022. 01/31/2022 [cited; Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus.

Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology—when less is more. N Engl J Med. 2021;385(16):1445–7.

Article  PubMed  Google Scholar 

Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, et al. Clinical development strategies and outcomes in first-in-human trials of monoclonal antibodies. J Clin Oncol. 2015;33(19):2158–65.

Article  CAS  PubMed  Google Scholar 

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4:72.

Article  PubMed  PubMed Central  Google Scholar 

Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Y, Li X, Cao Y. Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discov Today. 2021;26(8):1980–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59.

Article  CAS  PubMed  Google Scholar 

Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):292–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometr Syst Pharmacol. 2017;6(1):49–57.

Article  CAS  Google Scholar 

Dolgos H, Trusheim M, Gross D, Halle JP, Ogden J, Osterwalder B, et al. Translational Medicine Guide transforms drug development processes: the recent Merck experience. Drug Discov Today. 2016;21(3):517–26.

Article  PubMed  Google Scholar 

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737–46.

Article  CAS  PubMed  Google Scholar 

Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, et al. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis. Cancer Lett. 2021;1(520):1–11.

Article  Google Scholar 

Lunsumio, INN-mosunetuzumab. https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf. 2022.

Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481–91.

Article  CAS  PubMed  Google Scholar 

Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, et al. Nivolumab exposure–response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res. 2017;23(18):5394–405.

Article  CAS  PubMed  Google Scholar 

Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I. Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development. Clin Pharmacol Ther. 2017;101(5):582–4.

Article  CAS  PubMed  Google Scholar 

Clemens PL, Yan X, Lokhorst HM, Lonial S, Losic N, Khan I, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2017;56(8):915–24.

Article  CAS  PubMed  Google Scholar 

Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometr Syst Pharmacol. 2017;6(1):58–66.

Article  CAS  Google Scholar 

Wang X, Feng Y, Bajaj G, Gupta M, Agrawal S, Yang A, et al. Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma. CPT Pharmacometr Syst Pharmacol. 2017;6(1):40–8.

Article  Google Scholar 

Paci A, Desnoyer A, Delahousse J, Blondel L, Maritaz C, Chaput N, et al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. Eur J Cancer. 2020;128:107–18.

Article  CAS  PubMed  Google Scholar 

Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608.

Article  CAS  PubMed  Google Scholar 

Dhillon S. Tebentafusp: first approval. Drugs. 2022.